CO6231037A2 - Anticuerpos anti-hepcidina y usos de los mismos - Google Patents
Anticuerpos anti-hepcidina y usos de los mismosInfo
- Publication number
- CO6231037A2 CO6231037A2 CO10047542A CO10047542A CO6231037A2 CO 6231037 A2 CO6231037 A2 CO 6231037A2 CO 10047542 A CO10047542 A CO 10047542A CO 10047542 A CO10047542 A CO 10047542A CO 6231037 A2 CO6231037 A2 CO 6231037A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- hepcidin
- human
- spr
- determined
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a anticuerpos monoclonales que se enlazan selectivamente a hepcidina-25 humana y son caracterizados por tener alta afinidad para hepcidina-25 humana y fuertes propiedades neutralizantes a hepcidina madura humana. Los anticuerpos de la invención, son útiles terapéuticamente para incrementar los niveles de hierro en suero, conteo de reticulocitos, conteo de células rojas de la sangre, hemoglobina, y/o hematócritos en un humano, y para el tratamiento y diagnosis de trastornos promovidos por hepcidina madura, tales como anemia, en un sujeto humano. 1.- Un anticuerpo, caracterizado porque selectivamente se enlaza a hepcidina-25 humana con un KD de aproximadamente 800 pM o menos como se determina por resonancia de plasmón de superficie (SPR) a 25 °C. 2.- El anticuerpo de conformidad con la reivindicación 1, caracterizado porque el anticuerpo tiene una velocidad de disociación (kdisoc) para hepcidina-25 humana entre aproximadamente 8.5 x 10-3 s-1 y aproximadamente 1.8 x 10-4 s-1 como se determina por SPR a 25 °C. 3.- El anticuerpo de conformidad con cualquiera de las reivindicaciones 1-2, caracterizado porque el anticuerpo tiene un KD para hepcidina-25 humana entre aproximadamente 400 pM hasta aproximadamente 30 pM como se determina por SPR a 25°C.4.- El anticuerpo de conformidad con cualquiera de las reivindicaciones 1-3, caracterizado porque el anticuerpo tiene un KD para hepcidina-25 humana entre aproximadamente 200 pM hasta aproximadamente 30 pM como se determina por SPR a 25 °C. 5.- El anticuerpo de conformidad con cualquiera de las reivindicaciones 1-4, caracterizado porque el anticuerpo tiene un IC50 entre aproximadamente 100 nM y aproximadamente 50 nM en un ensayo in vitro de bioactividad hepcidina-25.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98491007P | 2007-11-02 | 2007-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6231037A2 true CO6231037A2 (es) | 2010-12-20 |
Family
ID=40383701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10047542A CO6231037A2 (es) | 2007-11-02 | 2010-04-22 | Anticuerpos anti-hepcidina y usos de los mismos |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US7820163B2 (es) |
| EP (2) | EP2527368B1 (es) |
| JP (1) | JP5469076B2 (es) |
| KR (2) | KR20120107145A (es) |
| CN (1) | CN103492414B (es) |
| AR (1) | AR069062A1 (es) |
| AU (1) | AU2008318850B2 (es) |
| BR (1) | BRPI0819211A2 (es) |
| CA (1) | CA2704527C (es) |
| CL (2) | CL2008003190A1 (es) |
| CO (1) | CO6231037A2 (es) |
| CR (1) | CR11414A (es) |
| CY (1) | CY1113630T1 (es) |
| DK (1) | DK2209806T3 (es) |
| DO (2) | DOP2010000123A (es) |
| EA (1) | EA023406B1 (es) |
| ES (1) | ES2392123T3 (es) |
| HK (1) | HK1142341A1 (es) |
| HR (1) | HRP20120870T1 (es) |
| IL (1) | IL205355A (es) |
| JO (1) | JO2828B1 (es) |
| MA (1) | MA31886B1 (es) |
| MX (1) | MX2010004841A (es) |
| MY (1) | MY155708A (es) |
| NZ (2) | NZ598391A (es) |
| PE (1) | PE20091261A1 (es) |
| PL (1) | PL2209806T3 (es) |
| PT (1) | PT2209806E (es) |
| RS (1) | RS52592B (es) |
| SI (1) | SI2209806T1 (es) |
| TN (1) | TN2010000201A1 (es) |
| TW (1) | TWI409276B (es) |
| UA (1) | UA98983C2 (es) |
| WO (1) | WO2009058797A1 (es) |
| ZA (1) | ZA201003025B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110053268A1 (en) * | 2006-10-17 | 2011-03-03 | Naohisa Tomosugi | Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator |
| JP2010517529A (ja) | 2007-02-02 | 2010-05-27 | アムジエン・インコーポレーテツド | ヘプシジン及びヘプシジン抗体 |
| JPWO2008146903A1 (ja) * | 2007-05-31 | 2010-08-19 | 直久 友杉 | 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法 |
| AR069062A1 (es) * | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| WO2009139822A1 (en) * | 2008-05-01 | 2009-11-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| NZ590863A (en) * | 2008-08-06 | 2012-10-26 | Lilly Co Eli | Anti-hepcidin-25 selective antibodies and uses thereof |
| DE102009034150A1 (de) * | 2009-07-20 | 2011-01-27 | Fresenius Medical Care Deutschland Gmbh | Adsorbens zur Adsorption von Hepcidin |
| WO2011020886A1 (de) | 2009-08-20 | 2011-02-24 | Vifor (International) Ag | Neue chinolin-hepcidin-antagonisten |
| AR077958A1 (es) | 2009-08-27 | 2011-10-05 | Vifor Int Ag | Quinoxalinonas antagonistas de la hepcidina |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| BR112012005119A2 (pt) | 2009-09-07 | 2016-11-22 | Vifor Int Ag | novos antagonistas de hepcidina etanodiaminas |
| AR078278A1 (es) | 2009-09-09 | 2011-10-26 | Vifor Int Ag | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. |
| WO2011071368A1 (en) | 2009-12-11 | 2011-06-16 | Umc St. Radboud | Method for measuring hepcidin |
| AU2011290751B2 (en) | 2010-08-16 | 2015-08-13 | Pieris Ag | Binding proteins for Hepcidin |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| EP2791684B1 (en) | 2011-12-12 | 2017-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| DK2968503T3 (en) * | 2013-03-15 | 2018-12-03 | Intrinsic Lifesciences Llc | ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF |
| US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| CN104945497B (zh) * | 2014-11-21 | 2018-04-03 | 南京国龙生物科技有限公司 | 一种新型抗菌肽Hep‑W及其制备方法和应用 |
| US10202444B2 (en) | 2015-02-24 | 2019-02-12 | Rpeptide, Llc | Anti-tau antibodies |
| WO2016146587A1 (en) | 2015-03-13 | 2016-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonists for use in the treatment of inflammation |
| TWI789343B (zh) | 2016-02-01 | 2023-01-11 | 丹麥商碩騰丹麥有限公司 | 微流體分析系統、執行分析的微流體匣及方法 |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM |
| ES2759622T3 (es) * | 2017-10-02 | 2020-05-11 | Certest Biotec S L | Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter |
| CN117903311A (zh) * | 2024-03-20 | 2024-04-19 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000073454A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6262247B1 (en) | 1999-08-30 | 2001-07-17 | Incyte Genomics, Inc. | Polycyclic aromatic hydrocarbon induced molecules |
| JP4944360B2 (ja) * | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
| CN1173737C (zh) | 2002-10-21 | 2004-11-03 | 钱忠明 | Hepcidin(海魄喜定)在制药中的应用 |
| US8017737B2 (en) | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| US7411048B2 (en) | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| EP1578254B1 (en) | 2002-11-19 | 2013-03-06 | DRG International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| WO2005033327A2 (en) | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
| US7723063B2 (en) * | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| US20090202986A1 (en) | 2004-10-22 | 2009-08-13 | Huse William D | Methods of optimizing antibody variable region binding affinity |
| WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| CA2602088C (en) | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
| JP2010517529A (ja) | 2007-02-02 | 2010-05-27 | アムジエン・インコーポレーテツド | ヘプシジン及びヘプシジン抗体 |
| CA2701694A1 (en) | 2007-10-02 | 2009-04-09 | Sophie Vaulont | Antigen-binding proteins having specificity for human hepcidin |
| AR069062A1 (es) | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| WO2009139822A1 (en) | 2008-05-01 | 2009-11-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| NZ590863A (en) * | 2008-08-06 | 2012-10-26 | Lilly Co Eli | Anti-hepcidin-25 selective antibodies and uses thereof |
-
2008
- 2008-10-27 AR ARP080104691A patent/AR069062A1/es unknown
- 2008-10-27 CL CL2008003190A patent/CL2008003190A1/es unknown
- 2008-10-27 PE PE2008001837A patent/PE20091261A1/es not_active Application Discontinuation
- 2008-10-27 TW TW097141237A patent/TWI409276B/zh not_active IP Right Cessation
- 2008-10-27 JO JO2008486A patent/JO2828B1/en active
- 2008-10-29 ES ES08844586T patent/ES2392123T3/es active Active
- 2008-10-29 PT PT08844586T patent/PT2209806E/pt unknown
- 2008-10-29 MX MX2010004841A patent/MX2010004841A/es active IP Right Grant
- 2008-10-29 RS RS20120466A patent/RS52592B/en unknown
- 2008-10-29 KR KR1020127023660A patent/KR20120107145A/ko not_active Application Discontinuation
- 2008-10-29 JP JP2010532186A patent/JP5469076B2/ja not_active Expired - Fee Related
- 2008-10-29 EA EA201070553A patent/EA023406B1/ru not_active IP Right Cessation
- 2008-10-29 AU AU2008318850A patent/AU2008318850B2/en not_active Ceased
- 2008-10-29 CA CA2704527A patent/CA2704527C/en not_active Expired - Fee Related
- 2008-10-29 UA UAA201005156A patent/UA98983C2/uk unknown
- 2008-10-29 SI SI200830773T patent/SI2209806T1/sl unknown
- 2008-10-29 EP EP12172307.6A patent/EP2527368B1/en active Active
- 2008-10-29 KR KR1020107009633A patent/KR101335059B1/ko not_active IP Right Cessation
- 2008-10-29 MY MYPI2010001992A patent/MY155708A/en unknown
- 2008-10-29 PL PL08844586T patent/PL2209806T3/pl unknown
- 2008-10-29 BR BRPI0819211-1A patent/BRPI0819211A2/pt not_active IP Right Cessation
- 2008-10-29 DK DK08844586.1T patent/DK2209806T3/da active
- 2008-10-29 WO PCT/US2008/081493 patent/WO2009058797A1/en active Application Filing
- 2008-10-29 EP EP08844586A patent/EP2209806B1/en active Active
- 2008-10-29 NZ NZ598391A patent/NZ598391A/xx not_active IP Right Cessation
- 2008-10-29 US US12/260,125 patent/US7820163B2/en not_active Expired - Fee Related
- 2008-10-29 CN CN200880114428.1A patent/CN103492414B/zh not_active Expired - Fee Related
- 2008-10-29 NZ NZ584997A patent/NZ584997A/en not_active IP Right Cessation
-
2010
- 2010-04-22 CO CO10047542A patent/CO6231037A2/es active IP Right Grant
- 2010-04-26 DO DO2010000123A patent/DOP2010000123A/es unknown
- 2010-04-26 IL IL205355A patent/IL205355A/en not_active IP Right Cessation
- 2010-04-30 TN TN2010000201A patent/TN2010000201A1/fr unknown
- 2010-04-30 MA MA32811A patent/MA31886B1/fr unknown
- 2010-04-30 ZA ZA2010/03025A patent/ZA201003025B/en unknown
- 2010-05-05 CR CR11414A patent/CR11414A/es not_active IP Right Cessation
- 2010-08-31 US US12/872,172 patent/US8329174B2/en active Active
- 2010-09-15 HK HK10108774.3A patent/HK1142341A1/xx not_active IP Right Cessation
-
2012
- 2012-06-22 CL CL2012001710A patent/CL2012001710A1/es unknown
- 2012-10-19 CY CY20121100986T patent/CY1113630T1/el unknown
- 2012-10-29 HR HRP20120870AT patent/HRP20120870T1/hr unknown
- 2012-12-07 US US13/708,059 patent/US8765129B2/en active Active
-
2013
- 2013-09-11 DO DO2013000205A patent/DOP2013000205A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6231037A2 (es) | Anticuerpos anti-hepcidina y usos de los mismos | |
| LTC2041177I2 (lt) | Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių | |
| BR112013031762A2 (pt) | proteínas solúveis para utilização como terapêuticos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| HRP20230844T1 (hr) | Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe | |
| CO6160305A2 (es) | Anticuerpos humanos de alta afinidad para el receptor de il-4 humano | |
| RU2014149681A (ru) | Антитела с множественной специфичностью | |
| EA201170312A1 (ru) | Селективные антитела к гепцидину-25 и их применение | |
| MX2012007318A (es) | Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| MA32725B1 (fr) | Anticorps contre l'il 17 humaine et utilisations associees | |
| BRPI0608281B8 (pt) | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende | |
| AR085334A1 (es) | Inmunoterapia mejorada, composicion farmaceutica, kit | |
| WO2010012004A3 (en) | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence | |
| JP2014515600A5 (es) | ||
| CN103298488A (zh) | 与α2整联蛋白结合的肽或肽复合物以及涉及所述肽或肽复合物的方法和用途 | |
| EP2931748A1 (en) | Bmp-6 antibodies | |
| MY159255A (en) | Antigen binding proteins specific for serum amyloid p component | |
| WO2007032804A3 (en) | Novel uses for anti-ige therapy | |
| JP2012510814A5 (es) | ||
| NZ592545A (en) | Anti-ferroportin 1 monoclonal antibodies and uses thereof | |
| Chauchet et al. | 265 CD47xPD-L1 bispecific antibodies for cancer therapy | |
| WO2013093122A3 (en) | Antibodies for the treatment and diagnosis of affective and anxiety disorders | |
| Kogan et al. | Immunological study of complex formation between soluble transferrin receptor and transferrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |